<DOC>
	<DOCNO>NCT01260012</DOCNO>
	<brief_summary>Liver fibrosis serious complication schistosomiasis mansoni . However limited proportion subject infection develop pathology limited knowledge risk factor differential morbidity pattern observe endemic community . Our preliminary cross-sectional study indicate serum level antioxidant may relate development fibrosis . The present project randomise double blind placebo control prospective study investigate role food base antioxidant supplement outcome anti-schistosomal chemotherapy regard extent fibrosis reversal .</brief_summary>
	<brief_title>Antioxidant Supplements Reversal Schistosomal Peri-portal Fibrosis</brief_title>
	<detailed_description>Schistosomiasis second lead parasitic disease worldwide , malaria . Liver fibrosis serious complication schistosomiasis mansoni lead reduce work capacity early death endemic country . There , however , limited knowledge development liver fibrosis differential pattern morbidity observe endemic community . Our preliminary cross-sectional study Ethiopia seem indicate serum level antioxidant may influence development fibrosis . The present project translational study combine basic antioxidant laboratory work randomise double blind placebo control prospective study endemic area Ethiopia , investigate role food base antioxidant supplement outcome anti-schistosomal chemotherapy regard extent fibrosis reversal . In addition , analysis dietary intake antioxidant among community comparable level S. mansoni infection differing level schistosomal periportal fibrosis undertaken compare serum level antioxidant prevalence liver fibrosis . Furthermore plan ass development schistosomal peri-portal fibrosis cohort student establish 9 year back comparable level community prevalence schistosomiasis differ access fruit vegetable . Research topic high priority globally line millennium development goal . Knowledge field also add understand fibrosis development general efficacy clinical treatment schistosomiasis particular .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Subjects schistosomal periportal fibrosis eligible study Subjects acute malaria , tuberculosis chronic diseases diabetes mellitus , cardiovascular disease cancer exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Schistosoma mansoni</keyword>
	<keyword>Schistosomiasis</keyword>
	<keyword>periportal fibrosis</keyword>
	<keyword>antioxidant</keyword>
	<keyword>fibrosis reversal</keyword>
</DOC>